FDA decision: Saroglitazar by Zydus Therapeutics (in 2026)

RegolamentazioneOne-OffHealth & Medicine6m

KalshiVerifica disponibilitàKYC richiesto2% di commissione

Probabilità implicita attuale

Sì 0%

Qualita del mercato

24 / 100

Bassa qualità

Volume 24h

0 €

Liquidità

0 €

Bassa liquidità

Bid / Ask

67.0% / 74.0%

Spread

10.4%

Spread ampio

Dati di mercato

Aggiornato 4 minuti fa

17 giu 26, 21:301 gen 27, 4:59

Trend

Esito24hProbabilità

Sì

100%

Esito scelto

Yes0%

Puntata (USDT)

Regole

If the FDA's decision on Saroglitazar by Zydus Therapeutics in 2026 is a full approval or an accelerated approval, the market resolves to Yes.

This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued.
Saroglitazar (sold under the brand name Lipaglyn in India) is an oral small-molecule drug developed by Zydus Therapeutics that is designed to simultaneously activate two molecular switches in the body — called PPAR-alpha and PPAR-gamma — which together regulate how the body handles fats and sugars.
Think of it like a dual-dial thermostat for metabolism: turning up both dials at once aims to reduce harmful lipid buildup and improve insulin sensitivity more effectively than nudging just one dial.
In the EPICS-III trial , it is being evaluated as a treatment for primary biliary cholangitis, a liver disease distinct from its original metabolic indications.

Mercati Correlati

Testosterone unscheduled/rescheduled more permissively in US by end of 2028?

994,7 €

Sì: 22.2%

MANIFOLD MARKETS

Will China have more phase 3 drug trials than the United States in year X?

367,9 €

2026: 33%

MANIFOLD MARKETS

Will estradiol be available over-the-counter in the US before 2030?

303 €

Sì: 8.2%

MANIFOLD MARKETS

FDA decision: DTX401 (pariglasgene brecaparvovec) by Ultragenyx Pharmaceutical (in 2026)

0 €

Sì: 0%

KALSHI

Hantavirus pandemic in 2026?

38,2K €

Sì: 4%

POLYMARKET

New pandemic in 2026?

5,2K €

Sì: 11%

POLYMARKET

Attivi in questi argomenti

BitcoinBTC$64,629.89-1.78%

EthereumETH$1,757.30-2.12%

SolanaSOL$72.45-1.60%

DogecoinDOGE$0.0864-1.25%

XRPXRP$1.19-2.24%

BNBBNB$603.36-0.41%

Notizie Correlate

Binance MiCA License Application Cleared by Greek Regulator, June 30 Update AwaitedBlockchain Reporter

CLARITY Act faces ethics showdown as David Nage eyes July voteCrypto News

Binance EU Access at Risk as Greek Regulator Set to Reject MiCA License BidBlockchain Reporter

Solana Institute warns Senate against weakening CLARITY ActCrypto News

Summer of crypto (regs): State of Crypto Coindesk

Philippine Central Bank Bars VASPs From Listing Privacy CoinsBlockchain Reporter

Regole

If the FDA's decision on Saroglitazar by Zydus Therapeutics in 2026 is a full approval or an accelerated approval, the market resolves to Yes.

This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued.
Saroglitazar (sold under the brand name Lipaglyn in India) is an oral small-molecule drug developed by Zydus Therapeutics that is designed to simultaneously activate two molecular switches in the body — called PPAR-alpha and PPAR-gamma — which together regulate how the body handles fats and sugars.
Think of it like a dual-dial thermostat for metabolism: turning up both dials at once aims to reduce harmful lipid buildup and improve insulin sensitivity more effectively than nudging just one dial.
In the EPICS-III trial , it is being evaluated as a treatment for primary biliary cholangitis, a liver disease distinct from its original metabolic indications.

FDA decision: Saroglitazar by Zydus Therapeutics (in 2026)

RegolamentazioneOne-OffHealth & Medicine6m

KalshiVerifica disponibilitàKYC richiesto2% di commissione

Probabilità implicita attuale

Sì 0%

Qualita del mercato

24 / 100

Bassa qualità

Volume 24h

0 €

Liquidità

0 €

Bassa liquidità

Bid / Ask

67.0% / 74.0%

Spread

10.4%

Spread ampio

Dati di mercato

Aggiornato 4 minuti fa

17 giu 26, 21:301 gen 27, 4:59

Trend

Esito24hProbabilità

Sì

100%

Esito scelto

Yes0%

Puntata (USDT)

Regole

If the FDA's decision on Saroglitazar by Zydus Therapeutics in 2026 is a full approval or an accelerated approval, the market resolves to Yes.

This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued.
Saroglitazar (sold under the brand name Lipaglyn in India) is an oral small-molecule drug developed by Zydus Therapeutics that is designed to simultaneously activate two molecular switches in the body — called PPAR-alpha and PPAR-gamma — which together regulate how the body handles fats and sugars.
Think of it like a dual-dial thermostat for metabolism: turning up both dials at once aims to reduce harmful lipid buildup and improve insulin sensitivity more effectively than nudging just one dial.
In the EPICS-III trial , it is being evaluated as a treatment for primary biliary cholangitis, a liver disease distinct from its original metabolic indications.

Mercati Correlati

Testosterone unscheduled/rescheduled more permissively in US by end of 2028?

994,7 €

Sì: 22.2%

MANIFOLD MARKETS

Will China have more phase 3 drug trials than the United States in year X?

367,9 €

2026: 33%

MANIFOLD MARKETS

Will estradiol be available over-the-counter in the US before 2030?

303 €

Sì: 8.2%

MANIFOLD MARKETS

FDA decision: DTX401 (pariglasgene brecaparvovec) by Ultragenyx Pharmaceutical (in 2026)

0 €

Sì: 0%

KALSHI

Hantavirus pandemic in 2026?

38,2K €

Sì: 4%

POLYMARKET

New pandemic in 2026?

5,2K €

Sì: 11%

POLYMARKET

Attivi in questi argomenti

BitcoinBTC$64,629.89-1.78%

EthereumETH$1,757.30-2.12%

SolanaSOL$72.45-1.60%

DogecoinDOGE$0.0864-1.25%

XRPXRP$1.19-2.24%

BNBBNB$603.36-0.41%

Notizie Correlate

Binance MiCA License Application Cleared by Greek Regulator, June 30 Update AwaitedBlockchain Reporter

CLARITY Act faces ethics showdown as David Nage eyes July voteCrypto News

Binance EU Access at Risk as Greek Regulator Set to Reject MiCA License BidBlockchain Reporter

Solana Institute warns Senate against weakening CLARITY ActCrypto News

Summer of crypto (regs): State of Crypto Coindesk

Philippine Central Bank Bars VASPs From Listing Privacy CoinsBlockchain Reporter

Regole

If the FDA's decision on Saroglitazar by Zydus Therapeutics in 2026 is a full approval or an accelerated approval, the market resolves to Yes.

This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued.
Saroglitazar (sold under the brand name Lipaglyn in India) is an oral small-molecule drug developed by Zydus Therapeutics that is designed to simultaneously activate two molecular switches in the body — called PPAR-alpha and PPAR-gamma — which together regulate how the body handles fats and sugars.
Think of it like a dual-dial thermostat for metabolism: turning up both dials at once aims to reduce harmful lipid buildup and improve insulin sensitivity more effectively than nudging just one dial.
In the EPICS-III trial , it is being evaluated as a treatment for primary biliary cholangitis, a liver disease distinct from its original metabolic indications.